CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which is focused on the acquisition, development and commercialization of therapeutics addressing cancer and other unmet medical needs. The company develops and commercializes the oncology drugs and drug candidates in China, Taiwan, Hong Kong, and Macau. Its products include Zevalin, Evomela, and Marqibo. The company was founded in 1991 and is headquartered in Rockville, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.

ROCKVILLE, Md. and BEIJING, Aug. 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the second quarter highlights at 8:00 a.m.

CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021

CASI Pharmaceuticals, Inc. (CASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate CASI Pharmaceuticals, Inc. (CASI) to Report a Decline in Earnings: What to Look Out for

ROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose escalation and expansion study of CID-103, an investigational novel anti-CD38 monoclonal antibody, in patients with previously treated, relapsed or refractory multiple myeloma.

CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma

ROCKVILLE, Md. and BEIJING, May 27, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference.

CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference

Infinity Pharma

IsoRay

PDS Biotechnology Corporation

Savara

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10

CASI Pharmaceuticals, Inc. (CASI) CEO Dr. Wei-Wu He on Q1 2021 Results - Earnings Call Transcript

Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 22.22% year over year to ($0.11), which missed the estimate of ($0.06).

CASI Pharmaceuticals: Q1 Earnings Insights

ROCKVILLE, Md. and BEIJING, May 13, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the first quarter of 2021.

CASI Pharmaceuticals Announces First Quarter 2021 Financial Results

ROCKVILLE, Md. and BEIJING, May 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call reviewing the first quarter highlights at 8:00 a.m.

CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021

The shares of CASI Pharmaceuticals Inc (NASDAQ: CASI) have received a $3.80 price target by Mizuho. These are the details.

CASI Stock: $3.80 Target By Mizuho

Avinger

Remark Hlds

Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383%

The stock price of CASI Pharmaceuticals, Inc. (Nasdaq: CASI) increased by over 10% pre-market. This is why it happened.

CASI Stock Price Increased Over 10% Pre-Market: Why It Happened

ROCKVILLE, Md. and BEIJING, March 30, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the year ended December 31, 2020 and provided an update on key highlights for 2021.

CASI Pharmaceuticals Announces Full Year 2020 Financial Results

Investors don't like that the company is hitting up the market for more cash.

Why CASI Pharmaceuticals Is Crashing Today

ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten public offering of 15,853,658 shares of its common stock at a price to the public of $2.05 per share.

CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common Stock

ROCKVILLE, Md. and BEIJING, March 23, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

ROCKVILLE, Md. and BEIJING, March 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call at 8:00 a.m.

CASI Pharmaceuticals To Host Business Update Call March 12, 2021

Cleave Therapeutics Inc has out-licensed CB-5339 to CASI Pharmaceuticals Inc (NASDAQ: CASI) in mainland China, Taiwan, Hong Kong, and Macau. Cleave and CASI will develop CB-5339 in both hematological malignancies and solid tumors under the terms of the agreement, with CASI responsible for development and commercialization in China and associated markets.

CASI Pharmaceuticals To Develop CB-5339 In Cancer Indications In China

ROCKVILLE, Md. and BEIJING, Jan. 21, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that its partner BioInvent International AB...

CASI Pharmaceuticals Partner, BioInvent, To Host Key Opinion Leader Call On BI-1206 For Relapsed Or Refractory Non-Hodgkin's Lymphoma

ROCKVILLE, Md., and BEIJING, Jan. 8, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that Dr. Wei-Wu He, Chairman and Chief...

CASI Pharmaceuticals, Inc. To Present At H.C. Wainwright Bioconnect Conference

ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces that the Chinese Center for Drug...

CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation

ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announces partner Juventas has completed the...

CASI Pharmaceuticals Announces Partner Juventas Completes $65 Million Financing And Initiates Registration Study For CNCT19 (CD19 CAR-T)

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript

Shares of CASI Pharmaceuticals (NASDAQ:CASI) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 40.00% over the past year to ($0.14), which missed the estimate of ($0.05).

CASI Pharmaceuticals: Q3 Earnings Insights

ROCKVILLE, MD., and BEIJING, Nov. 5, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference call...

News for CASI Pharmaceuticals Stock (CASI)